Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 73 Results

Title
Intervention Indication Therapeutic Area Year Actions
Talimogene laherparepvec in addition to pembrolizumab for metastatic melanoma Pembrolizumab (Keytruda; MK-3475) , Talimogene laherparepvec (Imlygic; T-Vec) Melanoma Skin Cancer 2020 View  |  Download
Pembrolizumab with stereotactic body radiotherapy for unresected stage I or II non-small cell lung cancer Pembrolizumab (Keytruda; MK-3475) , Stereotactic body radiotherapy Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Pembrolizumab with radiotherapy and chemotherapy for treating unresectable oesophageal cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) , Radiotherapy Oesophageal cancer Head and Neck Cancer 2023 View  |  Download
Pembrolizumab with or without standard adjuvant therapy after resection for nonsmall-cell lung cancer - adjuvant Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Pembrolizumab with or without olaparib following pembrolizumab with chemoradiation therapy for previously untreated, advanced, stage III non-small-cell lung cancer Chemoradiotherapy , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer Chemoradiotherapy , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Colorectal cancer Gastroenterology , Oncology 2022 View  |  Download
Pembrolizumab with lenvatinib and chemotherapy for the treatment of metastatic squamous cell oesophageal carcinoma Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Squamous cell oesophageal carcinoma Head and Neck Cancer 2024 View  |  Download
Pembrolizumab with Lenvatinib and chemotherapy for previously untreated advanced or metastatic gastroesophageal adenocarcinoma Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Gastroesophageal adenocarcinoma Gastrointestinal Cancer 2023 View  |  Download
Pembrolizumab with enzalutamide for treating
metastatic castration-resistant prostate cancer
Enzalutamide (Xtandi; MDV3100) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
1 2 3 7 8
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications